Corbus Pharmaceuticals (CRBP) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CRBP Corbus Pharmaceuticals

Watchlist

7.4700
-0.0300-0.40%

Close Feb 26 16:00 ET

7.2046
-0.2654-3.55%

Post 20:01 ET

90.98MMarket Cap-1.59P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Corbus PharmaceuticalsFeb 25 00:00 ET
Corbus Pharmaceuticals Holdings Inc. Stock Falls 7.5%, Underperforms Competitors
Dow JonesFeb 24 16:32 ET
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $60
Moomoo NewsFeb 18 08:31 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Cybin (CYBN) and Corbus Pharmaceuticals (CRBP)
TipRanksFeb 18 07:50 ET · Ratings
Promising Potential of Corbus Pharmaceuticals' CRB-701 in Oncology: A Strong Buy Rating by Andrew Fein
TipRanksFeb 18 07:06 ET · Ratings
Cannabis Stock Movers For February 17, 2025
BenzingaFeb 17 15:30 ET

Comments

Teddy123

Feb 14 06:36

Medical Research analysis

$Corbus Pharmaceuticals (CRBP.US)$
The Phase 1 clinical trial results for CRB-701 represent a significant advancement in the antibody-drug conjugate (ADC) space, particularly in addressing the historical challenges of ADC toxicity profiles. The observed 4% combined rate of peripheral neuropathy across both Western and Chinese studies is notably lower than existing ADC treatments, where rates can exceed 30-50% with current standard-of-care options.
The drug's differentiat...

Teddy123

Feb 14 06:35

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

$Corbus Pharmaceuticals (CRBP.US)$
Breakthrough Cancer Drug CRB-701 Delivers Powerful Results in Phase 1 Trial: Multiple Tumor Types Respond

Teddy123

Feb 11 06:44

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

$Corbus Pharmaceuticals (CRBP.US)$
Corbus Pharma's Cancer Drug CRB-701 Advances: Key Clinical Data Coming at ASCO-GU - Patient Enrollment Exceeds Targets